The second, obinutuzumab (Gazyva®), an anti-MS4A1 (CD20) mAb with low fucose content, has been approved for treatment of chronic lymphocytic leukemia (CLL) (Golay et al, 2013). This evidence concerns the gene MS4A1 and B-cell chronic lymphocytic leukemia.